Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Metabolon raises additional $6 million in its Series C funding round

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.

27 Oct 2009

Third-quarter fiscal 2009 results announced by QLT

QLT Inc. today reported financial results for the third quarter ended September 30, 2009.

27 Oct 2009

Princeton University scientists and researchers team up to explore cancer evolution

Princeton University physical scientists will partner with researchers at four other institutions to explore the driving forces behind the evolution of cancer under a five-year, $15.2 million award from the National Cancer Institute.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

Officials question validity of community research center cancer studies

The New York Times reports that the whistleblowing of a former vice president of a research hospital in Urbana, Ill., has highlighted some questionable research practices at certain community cancer research sites.

24 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies’ collaboration formed in October 2007.

22 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

A new study debating the effectiveness of minimally invasive prostate surgery is not telling the whole story, warns Dr. David B. Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York.

21 Oct 2009

Herrick Foundation's $3M grant for cancer research

The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.

21 Oct 2009

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues.

21 Oct 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Hope for lung cancer patients

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Astellas enters into agreement with Medivation to develop MDV3100

Metabolon raises additional $6 million in its Series C funding round

Third-quarter fiscal 2009 results announced by QLT

Princeton University scientists and researchers team up to explore cancer evolution

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Results from Phase I dose-escalation study of AT-101 announced

Officials question validity of community research center cancer studies

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

Early diagnostic for ovarian cancer to be developed

Celgene announces fiscal 2009 third-quarter results

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Professor secures grant for further research on immunotherapy strategies

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

Herrick Foundation's $3M grant for cancer research

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in